QUIGLEY TO BEGIN TESTING OF DRUG FOR DIABETES COMPLICATIONS

Quigley will begin patient screening and enrollment for the first of two Phase II trials to determine the safety profile of its drug candidate QR-333.

In an earlier proof-of-concept study, completed in France, QR-333 improved 67 percent of the key symptoms associated with this complication of diabetes, suggesting efficacy, the company said in a statement.